Why is the Imugene share price one of the biggest ASX 200 fallers today?

Imugene is the worst performing ASX 200 healthcare stock on Tuesday.

| More on:
A disappointed lab researcher sits in her lab looking at her clipboard with her hand to her face as she worries about the Imugene share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Tuesday has brought more pain for the Imugene share price. It's currently down 12% at 13 cents 
  • That's despite seemingly positive news on the trial of its cancer-fighting virus hitting the headlines
  • Imugene management reassured investors last month that the company is doing fine despite the downturn in its share price in 2022

The Imugene Limited (ASX: IMU) share price is struggling on Tuesday despite the company's silence.

Though, the biotechnology company has hit the headlines again today regarding the trial for its cancer-fighting virus, CF33-hNIS.

The first patient was dosed using the virus therapy as part of the trial last month.

At the time of writing, the Imugene share price is 13 cents, 12% lower than its previous close.

According to the ASX website, it is the seventh biggest faller among ASX 200 shares today.

For context, the S&P/ASX 200 Index (ASX: XJO) is 4.4% lower due to a widespread market sell-off.

Let's take a closer look at what's happening with Imugene's stock on Tuesday.

What's going wrong for the Imugene share price?

The Imugene share price is suffering on Tuesday despite a positive headline relating to the trial of the company's CF33-hNIS therapy.

The phase one trial could soon be kicked up a notch as additional patients reportedly wait to receive the therapy.

"The FDA has mandated that you have to wait 28 days before you can dose another patient, because you really want to have that safety profile," Imugene CEO Leslie Chong told Australian Associated Press in an article published by Yahoo Finance. "So we're just simply waiting for those 28 days."

Imugene announced the first patient was dosed with the cancer-fighting virus on 18 May. Tomorrow represents 28 days since the news was released.

By all accounts it's going well, with Chong commenting:

I'm always pleased when I don't hear anything, because that means that the patient had lots of safety, and we haven't heard anything – so we're really pleased.

Additionally, a non-price sensitive disclosure to the ASX this morning shows an increase in the Imugene shareholdings of one of the company's directors.

Charles Walker's indirect holding in the company was upped by 128,000 shares last week. Those shares were purchased on market for 15.5 cents.

The Imugene share price is the worst performer of the S&P/ASX 200 Health Care (ASX: XHJ) index today.

Right now, the sector is down 4.2% with only one of its constituents – Polynovo Ltd (ASX: PNV) — recording a gain.

Imugene wrote to shareholders last month, saying it is "as strong as it ever has been" despite recent struggles for the share price.

The stock has fallen 69% in 2022 so far. It's also 61% lower than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »